Amycretin vs Tirzepatide: How They Compare

Amycretin and tirzepatide aren’t really competitors yet, because only one of them is available. Tirzepatide (sold as Zepbound and Mounjaro) is FDA approved, on the market, and the most effective weight loss medication currently available. Amycretin is Novo Nordisk’s investigational next-generation drug, still in trials, that aims for strong results and adds a pill option. They work through different hormone combinations, and amycretin is years from any approval. If you’re weighing them, the practical takeaway is simple: tirzepatide works now, while amycretin is a future possibility.

What Is Tirzepatide?

Tirzepatide is a once-weekly injection that activates two hormone receptors, GLP-1 and GIP. It’s sold as Zepbound (for weight loss) and Mounjaro (for type 2 diabetes), and it’s currently the most effective approved obesity medication. In its main obesity trial (SURMOUNT-1), tirzepatide produced about 21% to 22.5% average weight loss at the highest dose over roughly 72 weeks. In a head-to-head trial against semaglutide (SURMOUNT-5), tirzepatide came out ahead. Beyond weight, it has proven benefits in obesity-related conditions, including heart failure with preserved ejection fraction in people with obesity. The key point: tirzepatide is available now, with a large, mature evidence base.

What Is Amycretin?

Amycretin is Novo Nordisk’s investigational next-generation drug. It activates GLP-1 (the same pathway tirzepatide uses, in part) plus amylin (a fullness hormone), all in a single molecule, and it’s being developed as both a weekly injection and a daily pill.

Early results are promising: injectable amycretin produced estimated weight loss of about 22% at 36 weeks in an early obesity study, and a November 2025 Phase 2 trial in people with type 2 diabetes showed up to about 14.5% with the injection and 10.1% with the pill. Both forms are entering Phase 3 in 2026, so amycretin is still years from a possible approval, and it isn’t available through TrimRx or anywhere else outside of clinical trials.

Amycretin vs Tirzepatide at a Glance

The Key Differences

Different second hormones

Both use GLP-1 to curb appetite. Tirzepatide adds GIP, which appears to improve how the body handles fat and may ease nausea compared with GLP-1 alone. Amycretin adds amylin, a separate fullness hormone. These are different strategies, and there’s no head-to-head data between them, so any efficacy comparison is indirect.

Available versus years away

This is the practical divide. Tirzepatide can be prescribed today. Amycretin is just entering Phase 3, so even in a best case it’s likely 2028 or later before approval. Choosing tirzepatide means starting now; “choosing” amycretin means waiting years for a drug that may or may not pan out.

The pill question

Amycretin’s daily-pill option is its standout feature, and it’s something tirzepatide (injection-only) doesn’t offer. For people set on avoiding needles, that matters. But amycretin’s pill results trail its own injection, and the comparison is moot until amycretin is actually on the market.

What the data shows

On paper, amycretin’s early 22% and tirzepatide’s roughly 21% to 22.5% look similar, but the comparison is shaky: tirzepatide’s figure comes from a large, completed Phase 3 obesity trial, while amycretin’s comes from a small, early study. Tirzepatide has the proven, large-scale evidence. Amycretin’s numbers are encouraging but preliminary.

Why Amycretin Isn’t Available Yet

Amycretin is investigational and still in mid-stage development, so it can’t be prescribed, and there’s no legal compounded version (compounding applies to approved medications, which amycretin is not). Any “research-use-only” peptide sold online as amycretin sits outside pharmacy oversight, with no assurance of purity, sterility, or correct dosing, and isn’t a safe or legal substitute. The trial doses mentioned here reflect what researchers used under supervision, not a plan to follow yourself.

What You Can Do Today

Tirzepatide is available now and is the most effective approved weight loss medication, so there’s a strong argument for starting it rather than waiting years for amycretin. The benefits accrue while you wait, not after, and the results tirzepatide can produce over a few months are well documented. If amycretin or another drug proves better later, switching is straightforward.

A licensed provider can help determine whether tirzepatide fits your health history and goals. TrimRx’s intake quiz is a simple place to start.

This article is for general educational purposes only and is not medical advice. Amycretin is an investigational drug that has not been approved by the FDA and is not available by prescription or through TrimRx; any product sold online as amycretin outside a clinical trial is unregulated and potentially unsafe. Tirzepatide is FDA approved but carries its own risks and is not appropriate for everyone. Weight loss figures reflect clinical trial findings and are not guarantees of individual results. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment, and never attempt to self-source or self-administer an investigational medication.